2025 年第 6 期 第 20 卷

贝伐珠单抗联合槐耳颗粒治疗非小细胞肺癌的临床研究

Clinical study of bevacizumab combined with Huaier granule in the treatment of non-small cell lung cancer

作者：年亮王佳王志尚

英文作者：Nian Liang Wang Jia Wang Zhishang

单位：延安大学附属医院肿瘤内科，延安716000

英文单位：Department of Oncology Medicine Yan′an University Affiliated Hospital Yan′an 716000 China

关键词：非小细胞肺癌；贝伐珠单抗；槐耳颗粒

英文关键词：Non-smallcelllungcancer;Bevacizumab;Huaiergranule

• 摘要：

• 目的 探讨贝伐珠单抗联合槐耳颗粒治疗非小细胞肺癌的效果。方法 选取2021年1月至2023年10月在延安大学附属医院进行治疗的84例非小细胞肺癌患者纳入本研究，按照随机数字表法分为对照组和观察组，各42例。在常规化疗基础上，对照组采用贝伐珠单抗注射液进行治疗，观察组采用贝伐珠单抗注射液联合槐耳颗粒进行治疗。2组均连续治疗12周。比较2组临床疗效、中医症状积分、血清肿瘤标志物水平、生活质量和不良反应发生情况。结果 观察组的疾病控制率明显高于对照组［85.7%(36/42)比66.7%(28/42)］，差异有统计学意义（P=0.040）。治疗后2组胸闷气憋、咳嗽不畅、大便干结、胸部疼痛积分均低于治疗前，且观察组均低于对照组，差异均有统计学意义（均P＜0.05）。治疗后2组糖类抗原125、胃泌素释放肽前体、癌胚抗原水平均低于治疗前，且观察组均低于对照组，差异均有统计学意义（均P＜0.05）。治疗后2组的躯体功能、社会功能、精神心理、总体感觉等评分均高于治疗前，且观察组均高于对照组，差异均有统计学意义（均P＜0.05）。2组恶心呕吐、肝肾功能异常、脱发、皮肤反应、毒性骨髓抑制发生率比较差异均无统计学意义（均P＞0.05）。结论 贝伐珠单抗联合槐耳颗粒治疗非小细胞肺癌具有较好的效果，对患者的中医症状积分、血清肿瘤标志物水平以及生活质量均有较好的改善作用。

• Objective To investigate the effect of bevacizumab combined with Huaier granule in the treatment of non-small cell lung cancer. Methods A total of 84 patients with non-small cell lung cancer who were treated in Yan′an University Affiliated Hospital from January 2021 to October 2023 were included in this study. According to the random number table method, they were divided into the control group and the observation group, with 42 cases in each group. On the basis of conventional treatment, the control group was treated with bevacizumab injection, and the observation group was treated with bevacizumab injection combined with Huaier granule. Both groups were treated for 12 weeks. The clinical efficacy, traditional Chinese medicine symptom score, tumor markers, quality of life and adverse reactions were compared between the two groups. Results The disease control rate of the observation group was significantly higher than that of the control group ［85.7%(36/42) vs 66.7%(28/42)］(P=0.040). After treatment, the scores of chest tightness, cough, dry stool and chest pain in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (all P＜0.05). After treatment, the levels of carbohydrate antigen 125, pro-gastrin-releasing peptide and carcinoembryonic antigen in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (all P＜0.05). After treatment, the scores of physical function, social function, mental psychology and general feeling of the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group (all P＜0.05). There was no significant difference in the incidence of nausea and vomiting, abnormal liver and kidney function, alopecia, skin reaction and toxic myelosuppression between the two groups (all P＞0.05). Conclusion Bevacizumab combined with Huaier granule in the treatment of non-small cell lung cancer has a good therapeutic effect, which can improve the traditional Chinese medicine symptoms, serum tumor markers and quality of life of patients.